RT Journal Article SR Electronic T1 Multi-level modeling of early COVID-19 epidemic dynamics in French regions and estimation of the lockdown impact on infection rate JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.04.21.20073536 DO 10.1101/2020.04.21.20073536 A1 Mélanie Prague A1 Linda Wittkop A1 Annabelle Collin A1 Dan Dutartre A1 Quentin Clairon A1 Philippe Moireau A1 Rodolphe Thiébaut A1 Boris P. Hejblum YR 2020 UL http://medrxiv.org/content/early/2020/07/13/2020.04.21.20073536.abstract AB We developed a multi-level model of the French COVID-19 epidemic at the regional level. We rely on a global extended Susceptible-Exposed-Infectious-Recovered (SEIR) mechanistic model as a simplified representation of the average epidemic process, with the addition of region specific random effects. Combining several French public datasets on the early dynamics of the epidemic, we estimate region-specific key parameters conditionally on this mechanistic model through Stochastic Approximation Expectation Maximization (SAEM) optimization using Monolix software. We thus estimate the basic reproductive numbers by region before lockdown (with a national average at 2.81 with 95% Confidence Interval [2.58; 3.07]), attack rates (i.e. percentages of infected people) over time per region which range between 1.9% and 9.9% as of May 11th, 2020, and the impact of nationwide lockdown on the infection rate which decreased the transmission rate by 76% towards reproductive numbers ranging from 0.63 to 0.73 at the end of lockdown across regions. These results confirm the low population immunity, the strong effect of the lockdown on the dynamics of the epidemics and the need for further intervention when lifting the lockdown to avoid an epidemic rebound.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by the GESTEPID Inria Mission COVID19.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are available on a github repository https://www.github.com/sistm/SEIRcovid19